# US 2010/0168021 A1 · Urocortin proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168021 A1
- Document ID: US20100168021A1
- Status: Published application
- Kind: A1
- Application number: 12/632,715
- Filed: 2009-12-07
- Published: 2010-07-01
- Earliest claimed: 2000-08-04
- Assignees: Research Development Foundation
- Inventors: Wylie Walker Vale, JR.; Teresa M. Reyes; Paul E. Sawchenko; Jean E. Rivier; Kathy A. Lewis; John B. Hogenesch; Joan M. Vaughan; Marilyn H. Perrin
- Web page: https://patentgrep.com/patent/US20100168021A1

## CPC

- C07K 14/57509: {Corticotropin releasing factor [CRF] (Urotensin)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.

## Claims

### Claim at position 1

-29. (canceled)

### Claim 30

A method of treating a pathophysiological state, comprising the step of administering a pharmaceutical composition comprising a human urocortin-related peptide protein having the amino acid sequence shown in SEQ ID NO:3 and a pharmaceutically acceptable carrier to an individual in need of such treatment.

### Claim 31 (depends on 30)

The method of claim 30, wherein said pathophysiological state is selected from the group consisting of high body temperature, appetite dysfunction, congestive heart failure, stress, anxiety, and undesirably low levels of ACTH secretion.

### Claim at position 4

-46. (canceled)

### Claim 47 (depends on 31)

The method of claim 31, wherein said pathophysiological state is congestive heart failure.

### Claim 48 (depends on 30)

The method of claim 30, wherein said peptide is amidated at the C-terminus.

### Claim 49 (depends on 48)

The method of claim 48, wherein said pathophysiological state is selected from the group consisting of high body temperature, appetite dysfunction, congestive heart failure, stress, anxiety, and undesirably low levels of ACTH secretion.

### Claim 50 (depends on 49)

The method of claim 49, wherein said pathophysiological state is congestive heart failure.

### Claim 51

A method of treating a pathophysiological state, comprising the step of administering a pharmaceutical composition comprising a human urocortin-related peptide protein having the amino acid sequence shown in SEQ ID NO:4 and a pharmaceutically acceptable carrier to an individual in need of such treatment.

### Claim 52 (depends on 51)

The method of claim 51, wherein said pathophysiological state is selected from the group consisting of high body temperature, appetite dysfunction, congestive heart failure, stress, anxiety, and undesirably low levels of ACTH secretion.

### Claim 53 (depends on 52)

The method of claim 52, wherein said pathophysiological state is congestive heart failure.

### Claim 54 (depends on 51)

The method of claim 51, wherein said peptide is amidated at the C-terminus.

### Claim 55 (depends on 54)

The method of claim 54, wherein said pathophysiological state is selected from the group consisting of high body temperature, appetite dysfunction, congestive heart failure, stress, anxiety, and undesirably low levels of ACTH secretion.

### Claim 56 (depends on 55)

The method of claim 55, wherein said pathophysiological state is congestive heart failure.

### Claim 57

A method of treating a pathophysiological state, comprising the step of administering a human urocortin-related peptide protein having the amino acid sequence shown in SEQ ID NO:3 to an individual in need of such treatment.

### Claim 58 (depends on 57)

The method of claim 57, wherein said pathophysiological state is selected from the group consisting of high body temperature, appetite dysfunction, congestive heart failure, stress, anxiety, and undesirably low levels of ACTH secretion.

### Claim 59 (depends on 58)

The method of claim 58, wherein said pathophysiological state is congestive heart failure.

### Claim 60 (depends on 57)

The method of claim 57, wherein said peptide is amidated at the C-terminus.

### Claim 61

A method of treating a pathophysiological state, comprising the step of administering a human urocortin-related peptide protein having the amino acid sequence shown in SEQ ID NO:4 to an individual in need of such treatment.

### Claim 62 (depends on 61)

The method of claim 61, wherein said pathophysiological state is selected from the group consisting of high body temperature, appetite dysfunction, congestive heart failure, stress, anxiety, and undesirably low levels of ACTH secretion.

### Claim 63 (depends on 62)

The method of claim 62, wherein said pathophysiological state is congestive heart failure.

### Claim 64 (depends on 60)

The method of claim 60, wherein said peptide is amidated at the C-terminus.
